Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GSR | P00390 | 3/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23515650 | 1.00 | MAPT (0.34) | MAPTGSRCA2 | |
| Nitric Acid SCHEMBL10869722 | 0.79 | CA5A (0.44) | MAPTGSRCA2 | |
| SCHEMBL19551024 | 0.72 | GSR (0.45) | GSRCA2 | |
| SCHEMBL16254272 | 0.72 | GSR (0.45) | GSRCA2 | |
| SCHEMBL3666798 | 0.72 | GSR (0.45) | GSRCA2 | |
| SCHEMBL16238007 | 0.72 | GSR (0.45) | GSRCA2 | |
| SCHEMBL19551025 | 0.72 | GSR (0.45) | GSRCA2 | |
| Nitric Acid SCHEMBL10346445 | 0.69 | CA5A (0.33) | MAPT | |
| SCHEMBL23284422 | 0.67 | — | — | |
| SCHEMBL209944 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324876-A1 | 4-SUBSTITUTED PYRANO[3,4,b]PYRAZINE KAPPA AGONISTS FOR TREATING DRUG DEPENDENCY | THE ROCKEFELLER UNIVERSITY | 2022-10-13 | — | — | US | disclosed |
| EP-3980018-A1 | 4-SUBSTITUTED PYRANO[3,4,B]PYRAZINE KAPPA AGONISTS FOR TREATING DRUG DEPENDENCY | The Rockefeller University (US) | 2022-04-13 | — | — | EP | disclosed |
| US-11091497-B2 | Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation | THE ROCKEFELLER UNIVERSITY (US) | 2021-08-17 | — | — | US | disclosed |
| US-20210179629-A1 | PYRANO[3,4-b]PYRAZINE KAPPA OPIOID RECEPTOR LIGANDS FOR TREATING ADDICTION, PRURITUS, PAIN, AND INFLAMMATION | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-17 | — | — | US | disclosed |
| WO-2020247599-A1 | 4-SUBSTITUTED PYRANO[3,4,B]PYRAZINE KAPPA AGONISTS FOR TREATING DRUG DEPENDENCY | THE ROCKEFELLER UNIVERSITY (US) | 2020-12-10 | — | — | WO | disclosed |
| EP-3723751-A1 | PYRANO[3,4-B]PYRAZINE KAPPA OPIOID RECEPTOR LIGANDS FOR TREATING ADDICTION, PRURITUS, PAIN, AND INFLAMMATION | The Rockefeller University (US) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019113419-A1 | PYRANO[3,4-B]PYRAZINE KAPPA OPIOID RECEPTOR LIGANDS FOR TREATING ADDICTION, PRURITUS, PAIN, AND INFLAMMATION | THE ROCKEFELLER UNIVERSITY (US) | 2019-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324876-A1 | 4-SUBSTITUTED PYRANO[3,4,b]PYRAZINE KAPPA AGONISTS FOR TREATING DRUG DEPENDENCY | OPRK1, OPRD1, OPRM1 | MAPT 2244/4885GSR 4009/4885CA2 4533/4885 |
| US-11091497-B2 | Pyrano[3,4-b]pyrazine kappa opioid receptor ligands for treating addiction, pruritus, pain, and inflammation | OPRK1, OPRD1, OPRL1 | MAPT 1467/4885GSR 3704/4885CA2 4621/4885 |
| US-20210179629-A1 | PYRANO[3,4-b]PYRAZINE KAPPA OPIOID RECEPTOR LIGANDS FOR TREATING ADDICTION, PRURITUS, PAIN, AND INFLAMMATION | OPRK1, OPRD1, OPRL1 | MAPT 1467/4885GSR 3704/4885CA2 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.